CytomX Therapeutics (CTMX) Stock Forecast, Price Target & Predictions
CTMX Stock Forecast
CytomX Therapeutics stock forecast is as follows: an average price target of $5.77 (represents a 369.11% upside from CTMX’s last price of $1.23) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CTMX Price Target
The average price target for CytomX Therapeutics (CTMX) is $5.77 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $3.50. This represents a potential 369.11% upside from CTMX's last price of $1.23.
CTMX Analyst Ratings
According to 5 Wall Street analysts, CytomX Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CTMX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CytomX Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Etzer Darout | BMO Capital | $3.56 | $1.18 | 201.69% | 189.43% |
| May 27, 2024 | Joseph Catanzaro | Piper Sandler | $3.50 | $1.75 | 100.00% | 184.55% |
| May 09, 2024 | Etzer Darout | BMO Capital | $3.59 | $4.19 | -14.32% | 191.87% |
| May 09, 2024 | Robert Driscoll | Wedbush | $8.00 | $2.40 | 233.46% | 550.41% |
| May 05, 2024 | Roger Song | Jefferies | $8.00 | $4.46 | 79.57% | 550.41% |
| Mar 12, 2024 | Roger Song | Jefferies | $2.50 | $2.15 | 16.28% | 103.25% |
| Mar 12, 2024 | Etzer Darout | BMO Capital | $3.25 | $2.15 | 51.16% | 164.23% |
| Jan 06, 2023 | - | BMO Capital | $3.20 | $1.79 | 78.77% | 160.16% |
| Nov 14, 2022 | - | BMO Capital | $2.60 | $1.29 | 101.55% | 111.38% |
The latest CytomX Therapeutics stock forecast, released on Aug 09, 2024 by Etzer Darout from BMO Capital, set a price target of $3.56, which represents a 201.69% increase from the stock price at the time of the forecast ($1.18), and a 189.43% increase from CTMX last price ($1.23).
CytomX Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $3.56 | $4.63 |
| Last Closing Price | $1.23 | $1.23 | $1.23 |
| Upside/Downside | -100.00% | 189.43% | 276.42% |
In the current month, the average price target of CytomX Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CytomX Therapeutics's last price of $1.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Aug 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Jun 27, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 27, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
| May 09, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 09, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| May 05, 2024 | Jefferies | - | Buy | Upgrade |
| Nov 08, 2023 | Wedbush | - | Outperform | Upgrade |
| Jan 06, 2023 | BMO Capital | Market Perform | Market Perform | Hold |
| Nov 14, 2022 | BMO Capital | - | Market Perform | Downgrade |
CytomX Therapeutics's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave CTMX a "Neutral" rating, the same as its previous rate.
CytomX Therapeutics Financial Forecast
CytomX Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.61M | $26.38M | $24.72M | $23.50M | $946.00K | $16.91M | - | $17.14M | $19.73M | $17.59M | $16.29M | $15.97M | $16.37M | $17.79M | $16.61M | $49.59M | $8.28M | $10.71M |
| Avg Forecast | $46.26M | $43.52M | $40.94M | $38.51M | $10.38M | $18.64M | $18.39M | $18.89M | $14.27M | $17.10M | $20.00M | $19.35M | $19.60M | $13.34M | $13.68M | $19.91M | $18.07M | $18.15M | $18.11M | $21.25M | $19.57M | $18.38M | $16.96M | $18.28M | $16.09M | $17.14M | $52.99M | $20.98M | $17.37M | $18.07M |
| High Forecast | $66.31M | $62.38M | $58.68M | $55.21M | $14.87M | $26.72M | $26.36M | $27.08M | $20.45M | $22.69M | $28.67M | $27.74M | $26.09M | $19.13M | $19.61M | $28.54M | $25.91M | $26.02M | $18.11M | $26.53M | $24.44M | $22.96M | $21.18M | $22.83M | $20.09M | $21.40M | $66.17M | $26.20M | $21.69M | $22.56M |
| Low Forecast | $21.13M | $19.88M | $18.70M | $17.60M | $4.74M | $8.52M | $8.40M | $8.63M | $6.52M | $10.85M | $9.14M | $8.84M | $12.58M | $6.10M | $6.25M | $9.10M | $8.26M | $8.29M | $18.11M | $11.55M | $10.64M | $9.99M | $9.22M | $9.94M | $8.74M | $9.31M | $28.80M | $11.40M | $9.44M | $9.82M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | 1.98% | 1.81% | 1.18% | 0.05% | 0.93% | - | 0.81% | 1.01% | 0.96% | 0.96% | 0.87% | 1.02% | 1.04% | 0.31% | 2.36% | 0.48% | 0.59% |
CytomX Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $19.35M, with a low forecast of $8.84M, and a high forecast of $27.74M. CTMX's average Quarter revenue forecast represents a -27.27% decrease compared to the company's last Quarter revenue of $26.61M (Dec 23).
CytomX Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-120.00K | $3.12M | $-2.74M | $-5.06M | $-28.08M | $-23.32M | - | $-23.36M | $-25.55M | $-21.90M | $-18.57M | $-14.88M | $-14.04M | $-14.06M | $-15.06M | $-1.07M | $-35.27M | $-23.02M |
| Avg Forecast | $-32.39M | $-30.47M | $-28.67M | $-26.97M | $-7.27M | $-13.05M | $-12.88M | $-13.23M | $-9.99M | $-11.97M | $-14.00M | $-31.41M | $-13.72M | $-9.34M | $-9.58M | $-28.55M | $-12.66M | $-20.08M | $-12.68M | $-22.57M | $-13.71M | $-18.25M | $-15.71M | $-18.71M | $-19.09M | $-18.74M | $-55.90M | $-2.47M | $-28.68M | $-22.57M |
| High Forecast | $-14.80M | $-13.92M | $-13.10M | $-12.32M | $-3.32M | $-5.96M | $-5.88M | $-6.04M | $-4.56M | $-7.59M | $-6.40M | $-25.13M | $-8.81M | $-4.27M | $-4.38M | $-22.84M | $-5.78M | $-16.06M | $-12.68M | $-18.06M | $-7.45M | $-14.60M | $-12.57M | $-14.97M | $-15.27M | $-15.00M | $-44.72M | $-1.97M | $-22.94M | $-18.06M |
| Low Forecast | $-46.43M | $-43.68M | $-41.09M | $-38.66M | $-10.41M | $-18.71M | $-18.46M | $-18.96M | $-14.32M | $-15.89M | $-20.08M | $-37.69M | $-18.27M | $-13.40M | $-13.73M | $-34.26M | $-18.14M | $-24.09M | $-12.68M | $-27.08M | $-17.12M | $-21.90M | $-18.85M | $-22.45M | $-22.91M | $-22.49M | $-67.08M | $-2.96M | $-34.41M | $-27.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | -0.33% | 0.29% | 0.18% | 2.22% | 1.16% | - | 1.04% | 1.86% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.43% | 1.23% | 1.02% |
6 analysts predict CTMX's average Quarter EBITDA for Dec 23 to be $-13.72M, with a high of $-8.81M and a low of $-18.27M. This is -539.45% lower than CytomX Therapeutics's previous annual EBITDA (Sep 23) of $3.12M.
CytomX Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $837.00K | $2.99M | $-1.09M | $-969.00K | $-26.58M | $-22.65M | - | $-23.80M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $12.21M | $-35.46M | $-23.70M |
| Avg Forecast | $-25.08M | $-24.45M | $-23.96M | $-24.06M | $-18.92M | $-11.62M | $-12.78M | $-11.58M | $-18.62M | $-14.63M | $-8.47M | $-32.31M | $-4.10M | $-16.01M | $-16.05M | $-29.38M | $-19.99M | $-20.70M | $-30.84M | $-23.22M | $-23.31M | $-18.82M | $-16.28M | $-19.55M | $-19.99M | $-19.61M | $-58.21M | $28.18M | $-28.83M | $-23.23M |
| High Forecast | $-7.37M | $-7.19M | $-7.04M | $-7.07M | $-5.56M | $-3.42M | $-3.76M | $-3.40M | $-5.47M | $10.97M | $-2.49M | $-25.85M | $16.39M | $-4.71M | $-4.72M | $-23.50M | $-5.88M | $-16.56M | $-30.84M | $-18.58M | $-9.48M | $-15.06M | $-13.03M | $-15.64M | $-15.99M | $-15.69M | $-46.57M | $33.81M | $-23.06M | $-18.59M |
| Low Forecast | $-39.22M | $-38.23M | $-37.46M | $-37.61M | $-29.58M | $-18.17M | $-19.98M | $-18.10M | $-29.10M | $-29.25M | $-13.24M | $-38.78M | $-24.59M | $-25.03M | $-25.09M | $-35.25M | $-31.26M | $-24.84M | $-30.84M | $-27.87M | $-30.85M | $-22.58M | $-19.54M | $-23.46M | $-23.99M | $-23.54M | $-69.85M | $22.54M | $-34.60M | $-27.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.20% | -0.19% | 0.07% | 0.03% | 1.33% | 1.09% | - | 1.03% | 1.13% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.43% | 1.23% | 1.02% |
CytomX Therapeutics's average Quarter net income forecast for Mar 24 is $-32.31M, with a range of $-38.78M to $-25.85M. CTMX's average Quarter net income forecast represents a -3960.54% decrease compared to the company's last Quarter net income of $837.00K (Dec 23).
CytomX Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $7.79M | $6.81M | $7.40M | $7.98M | $10.07M | $10.49M | - | $10.54M | $9.46M | $11.09M | $9.39M | $9.23M | $9.14M | $8.63M | $8.68M | $9.57M | $9.22M | $8.46M |
| Avg Forecast | $24.63M | $23.17M | $21.80M | $20.51M | $5.52M | $9.93M | $9.79M | $10.06M | $7.60M | $9.11M | $10.65M | $14.26M | $10.44M | $7.11M | $7.28M | $12.97M | $9.62M | $10.16M | $9.65M | $10.25M | $10.42M | $9.24M | $7.95M | $11.60M | $12.44M | $11.51M | $32.22M | $11.17M | $7.49M | $8.30M |
| High Forecast | $35.31M | $33.22M | $31.25M | $29.40M | $7.92M | $14.23M | $14.04M | $14.42M | $10.89M | $12.08M | $15.27M | $17.12M | $13.89M | $10.19M | $10.44M | $15.56M | $13.80M | $12.19M | $9.65M | $12.30M | $13.02M | $11.09M | $9.54M | $13.92M | $14.92M | $13.81M | $38.67M | $13.95M | $8.99M | $9.96M |
| Low Forecast | $11.25M | $10.59M | $9.96M | $9.37M | $2.52M | $4.54M | $4.47M | $4.60M | $3.47M | $5.78M | $4.87M | $11.41M | $6.70M | $3.25M | $3.33M | $10.37M | $4.40M | $8.13M | $9.65M | $8.20M | $5.66M | $7.39M | $6.36M | $9.28M | $9.95M | $9.21M | $25.78M | $6.07M | $6.00M | $6.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.96% | 1.02% | 0.62% | 1.05% | 1.03% | - | 1.03% | 0.91% | 1.20% | 1.18% | 0.80% | 0.74% | 0.75% | 0.27% | 0.86% | 1.23% | 1.02% |
CytomX Therapeutics's average Quarter SG&A projection for Mar 24 is $14.26M, based on 3 Wall Street analysts, with a range of $11.41M to $17.12M. The forecast indicates a 83.09% rise compared to CTMX last annual SG&A of $7.79M (Dec 23).
CytomX Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 4 | 8 | 5 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.01 | $0.04 | $-0.02 | $-0.01 | $-0.40 | $-0.34 | - | $-0.36 | $-0.40 | $-0.35 | $-0.30 | $-0.26 | $-0.32 | $-0.32 | $-0.34 | $0.27 | $-0.78 | $-0.52 |
| Avg Forecast | $-0.30 | $-0.29 | $-0.28 | $-0.28 | $-0.22 | $-0.14 | $-0.15 | $-0.14 | $-0.22 | $-0.17 | $-0.10 | $-0.10 | $-0.05 | $-0.19 | $-0.19 | $-0.11 | $-0.24 | $-0.30 | $-0.37 | $-0.36 | $-0.35 | $-0.31 | $-0.32 | $-0.35 | $-0.50 | $-0.48 | $0.16 | $-0.45 | $-0.47 | $-0.52 |
| High Forecast | $-0.09 | $-0.08 | $-0.08 | $-0.08 | $-0.07 | $-0.04 | $-0.04 | $-0.04 | $-0.06 | $0.13 | $-0.03 | $-0.03 | $0.19 | $-0.06 | $-0.06 | $-0.03 | $-0.07 | $-0.09 | $-0.37 | $-0.15 | $-0.14 | $-0.13 | $-0.13 | $-0.14 | $-0.20 | $-0.19 | $0.21 | $-0.18 | $-0.19 | $-0.21 |
| Low Forecast | $-0.46 | $-0.45 | $-0.44 | $-0.44 | $-0.35 | $-0.21 | $-0.24 | $-0.21 | $-0.34 | $-0.34 | $-0.16 | $-0.16 | $-0.29 | $-0.29 | $-0.30 | $-0.17 | $-0.37 | $-0.48 | $-0.37 | $-0.47 | $-0.46 | $-0.41 | $-0.42 | $-0.46 | $-0.67 | $-0.63 | $0.06 | $-0.59 | $-0.62 | $-0.69 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.26% | -0.20% | 0.09% | 0.13% | 1.70% | 1.12% | - | 1.01% | 1.15% | 1.12% | 0.94% | 0.75% | 0.63% | 0.67% | -2.17% | -0.61% | 1.65% | 0.99% |
According to 3 Wall Street analysts, CytomX Therapeutics's projected average Quarter EPS for Mar 24 is $-0.10, with a low estimate of $-0.16 and a high estimate of $-0.03. This represents a -923.15% decrease compared to CTMX previous annual EPS of $0.01 (Dec 23).
CytomX Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
CTMX Forecast FAQ
Is CytomX Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, CytomX Therapeutics (CTMX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of CTMX's total ratings.
What is CTMX's price target?
CytomX Therapeutics (CTMX) average price target is $5.77 with a range of $3.5 to $8, implying a 369.11% from its last price of $1.23. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CytomX Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CTMX stock, the company can go up by 369.11% (from the last price of $1.23 to the average price target of $5.77), up by 550.41% based on the highest stock price target, and up by 184.55% based on the lowest stock price target.
Can CytomX Therapeutics stock reach $2?
CTMX's average twelve months analyst stock price target of $5.77 supports the claim that CytomX Therapeutics can reach $2 in the near future.
What are CytomX Therapeutics's analysts' financial forecasts?
CytomX Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $66.3M (high $95.04M, low $30.29M), average EBITDA is $-46.426M (high $-21.211M, low $-66.55M), average net income is $-54.902M (high $-16.138M, low $-85.84M), average SG&A $35.3M (high $50.61M, low $16.13M), and average EPS is $-0.647 (high $-0.19, low $-1.011). CTMX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $169.23M (high $242.58M, low $77.32M), average EBITDA is $-119M (high $-54.141M, low $-170M), average net income is $-97.553M (high $-28.675M, low $-153M), average SG&A $90.11M (high $129.18M, low $41.17M), and average EPS is $-1.149 (high $-0.338, low $-1.797).
Did the CTMX's actual financial results beat the analysts' financial forecasts?
Based on CytomX Therapeutics's last annual report (Dec 2023), the company's revenue was $101.21M, beating the average analysts forecast of $66.53M by 52.12%. Apple's EBITDA was $-6.484M, missing the average prediction of $-61.199M by -89.41%. The company's net income was $-569K, missing the average estimation of $-65.53M by -99.13%. Apple's SG&A was $30.02M, missing the average forecast of $37.79M by -20.57%. Lastly, the company's EPS was $0, missing the average prediction of $-0.537 by -100.00%. In terms of the last quarterly report (Dec 2023), CytomX Therapeutics's revenue was $26.61M, beating the average analysts' forecast of $19.6M by 35.76%. The company's EBITDA was $-120K, missing the average prediction of $-13.724M by -99.13%. CytomX Therapeutics's net income was $837K, missing the average estimation of $-4.099M by -120.42%. The company's SG&A was $7.79M, missing the average forecast of $10.44M by -25.36%. Lastly, the company's EPS was $0.0124, missing the average prediction of $-0.0483 by -125.68%